BIO vs. GSK: Bio-Rad Laboratories vs. GSK Stock Comparison

Company Profile

Bio-Rad Laboratories (BIO) and GSK (GSK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO is classified in Life Sciences Tools & Services while GSK is classified in Pharmaceuticals.

Bio-Rad Laboratories (BIO) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Bio-Rad Laboratories (BIO) at 14.27% and GSK (GSK) at 28.27% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Bio-Rad Laboratories (BIO) at 39.45% keeps the most of each sales dollar — above its industry’s net margin range — and GSK (GSK) at 12.97% also retains a top-quartile share.

GSK (GSK) at 32.14% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Bio-Rad Laboratories (BIO) at 0.65% and GSK (GSK) at 4.11% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: GSK (GSK) reports EPS growth of 123.15%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while GSK (GSK) at 0.86 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GSK.

Bio-Rad Laboratories (BIO) at 0.18 carries an industry-typical debt-to-equity mix, while GSK (GSK) at 1.30 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Bio-Rad Laboratories (BIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a yield of 1.57%, ranking against industry peers normally.

Bio-Rad Laboratories (BIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a payout of 63.33%, ranking against industry peers normally.

Dividend Metrics

Valuation

Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while GSK (GSK) at 17.54 is closer to its industry’s usual earnings multiple — a discount for BIO, though growth and earnings durability still matter.

GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while Bio-Rad Laboratories (BIO) at 3.96 prices around its industry’s middle — GSK costs less per dollar of sales, though read it alongside growth and margins.

Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile against book while GSK (GSK) at 4.02 is valued near its industry’s middle — BIO is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics